Reuters logo
7 months ago
BRIEF-Alexion submits U.S. and EU applications seeking approval of Soliris as a treatment for patients with refractory generalized myasthenia gravis
January 9, 2017 / 11:49 AM / 7 months ago

BRIEF-Alexion submits U.S. and EU applications seeking approval of Soliris as a treatment for patients with refractory generalized myasthenia gravis

1 Min Read

Jan 9 (Reuters) - Alexion Pharmaceuticals Inc

* Alexion submits U.S. and EU applications seeking approval of Soliris (eculizumab) as a treatment for patients with refractory generalized myasthenia gravis (gMG)

* Alexion Pharmaceuticals Inc - Both U.S. and EU submissions are supported by comprehensive data from phase 3 regain study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below